Agios Pharmaceuticals is cutting the company’s staff numbers by 50 as part of plans to lay low on exploratory research efforts to focus on the success of late-stage initiatives.

Rubius Therapeutics is minimizing the focus on the company’s rare disease pipeline and taking greater aim at developing treatments for cancer and autoimmune diseases.